|
|||||
|
|
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines |
|
| Institution: | 1. Medicago Inc., 1020 route de l’Église office 600, Québec, QC G1V 3V9, Canada;2. GlaxoSmithKline Biologicals, Rue de l''Institut 89, 1330 Rixensart, Belgium;3. Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, QC H4A 3J1, Canada |
| Abstract: | Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the coronavirus disease 2019 (COVID-19) has afflicted hundreds of millions of people in a worldwide pandemic. Several safe and effective COVID-19 vaccines are now available. However, the rapid emergence of variants and risk of viral escape from vaccine-induced immunity emphasize the need to develop broadly protective vaccines. A recombinant plant-derived virus-like particle vaccine for the ancestral COVID-19 (CoVLP) recently authorized by Canadian Health Authorities and a modified CoVLP.B1351 targeting the B.1.351 variant (both formulated with the adjuvant AS03) were assessed in homologous and heterologous prime-boost regimen in mice. Both strategies induced strong and broadly cross-reactive neutralizing antibody (NAb) responses against several Variants of Concern (VOCs), including B.1.351/Beta, B.1.1.7/Alpha, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/Omicron strains. The neutralizing antibody (NAb) response was robust with both primary vaccination strategies and tended to be higher for almost all VOCs following the heterologous prime-boost regimen. |
| Keywords: | SARS-CoV-2 COVID-19 vaccine Virus-like particle AS03 Heterologous regimen Variant of concerns Cross-neutralization ACC"} {"#name":"keyword" "$":{"id":"pc_zxBqq4z7ND"} "$$":[{"#name":"text" "_":"Animal Care Committee ACE2"} {"#name":"keyword" "$":{"id":"pc_Nc4RSTfhqF"} "$$":[{"#name":"text" "_":"Angiotensin-Converting Enzyme CoVLP"} {"#name":"keyword" "$":{"id":"pc_Hlkrss2UiP"} "$$":[{"#name":"text" "_":"Coronavirus-Like Particle CI"} {"#name":"keyword" "$":{"id":"pc_m8VIzK9pR8"} "$$":[{"#name":"text" "_":"Confidence Interval CT"} {"#name":"keyword" "$":{"id":"pc_EIzg4TwoK9"} "$$":[{"#name":"text" "_":"Cytoplasmic Tail GMT"} {"#name":"keyword" "$":{"id":"pc_97obFONyU6"} "$$":[{"#name":"text" "_":"Geometric Mean IM"} {"#name":"keyword" "$":{"id":"pc_7MzbkxEJyt"} "$$":[{"#name":"text" "_":"Intramuscular/Intramuscularly MRD"} {"#name":"keyword" "$":{"id":"pc_PI9UaR4WpW"} "$$":[{"#name":"text" "_":"Minimum Required Dilution NAb"} {"#name":"keyword" "$":{"id":"pc_z3Jllrjjec"} "$$":[{"#name":"text" "_":"Neutralizing Antibody PBS"} {"#name":"keyword" "$":{"id":"pc_K7IBlLixyW"} "$$":[{"#name":"text" "_":"Phosphate Buffered Saline PNA"} {"#name":"keyword" "$":{"id":"pc_SJbegvjiJs"} "$$":[{"#name":"text" "_":"Pseudovirus Neutralizing Assay RBD"} {"#name":"keyword" "$":{"id":"pc_tIOt6uVcHO"} "$$":[{"#name":"text" "_":"Receptor Binding Domain S"} {"#name":"keyword" "$":{"id":"pc_VDk1dZzXjz"} "$$":[{"#name":"text" "_":"Spike TM"} {"#name":"keyword" "$":{"id":"pc_tLyebfUIay"} "$$":[{"#name":"text" "_":"Transmembrane Domain VOC"} {"#name":"keyword" "$":{"id":"pc_yEcRDn6c8r"} "$$":[{"#name":"text" "_":"Variant of Concern WHO"} {"#name":"keyword" "$":{"id":"pc_CXKWdG3QSG"} "$$":[{"#name":"text" "_":"World Health Organisation |
| 本文献已被 ScienceDirect 等数据库收录！ | |